Working Note: Tongyang Life

Knowledge Snapshot

This file is not reading material for humans, but a handoff file for a new research agent with zero prior knowledge to reconstruct the initial context for the target issuer. It records objective context so that already confirmed matters can be taken over without additional research.

Detailed financial data, earnings series, debt details, segment figures, and rating histories should generally be placed in data/*.json. Do not copy entire numerical tables here; leave the company profile, credit structure, credit-relevant conditions and trends that can be confirmed from financial data, and major confirmed facts here. Monitoring judgments, unresolved issues, research and writing cautions, and wording cautions should be placed in issuer_notes.md.

Last updated: 2026-06-12

Issuer Overview

• Tongyang Life Insurance Co., Ltd. is a Korean life insurer listed on KOSPI under code 082640. It should be treated as a meaningful mid-sized Korean life insurer rather than a dominant top-tier franchise.
• Woori Financial Group completed the acquisition of a controlling stake in 2025 and has announced a share exchange process intended to make Tongyang Life and ABL Life wholly owned subsidiaries. The full-subsidiary process had not been completed as of the latest report material reviewed.

Core Credit View

• The credit profile has two layers: the standalone insurance company and expected support from Woori Financial Group.
• Standalone credit is supported by protection-oriented insurance business, sizeable investment assets, regulatory solvency above the minimum, and access to subordinated capital markets.
• Standalone constraints are moderate K-ICS headroom, volatile earnings under IFRS 17, market-sensitive investment profit and OCI, ALM exposure, and the need to prove stable performance under Woori ownership.
• Woori ownership is a credit positive because it increases strategic importance and support expectations, but it is not a legal guarantee for Tongyang Life's debt.

Business and Franchise View

• The company operates in the Korean life insurance market with protection, survival, endowment, group, and separate-account / variable products.
• Protection-type insurance is the core business mix. It can support CSM and insurance service profit if pricing, claims, persistency, and assumption management remain disciplined.
• The franchise may benefit from Woori group distribution and customer access over time, but realized bancassurance, ABL Life coordination, and integration benefits remain to be demonstrated.

Capital Structure and Structural Points

• Regulatory capital is above the minimum but should be monitored as a moderate buffer for a long-duration life insurer rather than a thick surplus position.
• The U.S.$500 million 6.25% Tier II Subordinated Sustainability Notes due 2035 are subordinated regulatory capital instruments. They include regulatory redemption conditions and potential principal write-down features in specified non-viability / insolvency circumstances.
• The Tier II notes should not be analysed as ordinary senior unsecured debt, and Woori support expectations should not be treated as changing the legal ranking or loss-absorption features of the notes.

Liquidity and Funding View

• Liquidity is supported by premium inflow, investment assets, capital-market access, and expected support from Woori Financial Group.
• Insurer liquidity analysis should separate policyholder obligations, regulatory-capital restrictions, subordinated note optional redemption, foreign-currency funding, and hedging / ALM needs.

Credit Strengths

• Expected support and strategic importance after inclusion under Woori Financial Group.
• Meaningful scale in the Korean life insurance market.
• Protection-oriented business base and potential Woori distribution benefits.
• Regulatory solvency above the minimum and demonstrated access to Tier II capital markets.

Credit Weaknesses

• Earnings have been volatile, with FY2025 weakness and Q1 2026 still below the prior-year quarter at the net-profit level.
• K-ICS headroom is not large for a market-sensitive life insurer.
• Investment profit, OCI, interest rates, FX, overseas securities, hedging, and ALM can materially affect capital and earnings.
• Integration with Woori and ABL Life is strategically positive but still carries execution risk.

Rating Watchpoints

• Future rating actions should be read through both standalone capital / earnings and parent-support notching.
• Public rating summaries have indicated investment-grade international ratings and strong domestic ratings, but direct full rating reports have not been retained locally.
• Any change in Woori support expectations, full-subsidiary process, capital policy, K-ICS ratio, or subordinated-debt treatment could affect the rating view.

Recurring Analytical Cautions

• Do not describe Woori support as a legal guarantee unless a binding guarantee is identified.
• Do not use preliminary or press-reported K-ICS figures when corrected DART figures are available.
• Do not treat CSM as cash; assess product mix, assumption quality, release sustainability, and onerous contract movements.
• Do not treat the 2030 first reset / call date of the Tier II notes as a firm repayment date.

Reliable Core Sources

• DART filings are the primary route for official Korean regulatory filings and corrected quarterly reports.
• SGX offering circular is the primary route for Tier II note terms.
• Woori Financial Group SEC and DART share-exchange disclosures are primary routes for the full-subsidiary process.
• Rating-agency original reports should be preferred when available; current retained rating information includes public summaries.

Issuer Notes

This file is not a work log for humans; it is a handoff file for transferring research and writing judgment to a newly assigned research agent with no prior knowledge. Record ongoing follow-up items, unresolved issues, company-specific analytical cautions, points to keep in mind in credit assessment, cautions on wording in reports, and items to check next time.

issuer_notes.md is not a change history. Do not leave work logs such as typo corrections, HTML regeneration, minor wording revisions, or validator runs.

Last updated: 2026-06-12

Ongoing Follow-Up Items

• Track Woori Financial Group's full-subsidiary / delisting process for Tongyang Life and ABL Life, including shareholder approvals, the expected August 2026 share exchange, and any updated integration plan.
• Monitor quarterly K-ICS, available capital, required capital, duration gap, subordinated-capital treatment, and the distance from any management target if disclosed.
• Follow quarterly IFRS 17 earnings quality: insurance service result, investment result, OCI, CSM movement, onerous contract costs, lapse / persistency, and assumption changes.
• Monitor investment-asset quality, overseas securities, hedging, FX, ALM mismatch, and market sensitivity.
• Check whether Woori announces a capital plan, merger timetable, bancassurance strategy, ABL Life coordination plan, or explicit support agreement.

Unresolved Issues and Items to Check Next Time

• Obtain and retain direct DART / company annual report files for the annual report, rather than relying on mirrored financial-report extracts for annual data.
• Review Q2 2026 official filing to confirm whether Q1 2026 insurance-profit improvement continues and whether investment profit / OCI volatility remains contained.
• Confirm current Fitch, Moody's, NICE, KIS, and Korea Ratings reports directly if access is available.
• Confirm whether any binding guarantee, keepwell, capital support agreement, or other enforceable support arrangement exists from Woori Financial Group.
• Recheck coupon deferral, redemption, non-viability, write-down, and regulatory approval provisions of the U.S.$500 million Tier II notes before any security-specific recommendation.

Analytical Cautions

• Analyse Tongyang Life through two layers: standalone insurance company risk and Woori support expectations.
• Treat Woori support as a credit-positive expectation, not as a legal guarantee unless binding documentation is found.
• Treat K-ICS improvement cautiously when it is driven by OCI or market movements rather than retained earnings and recurring insurance profit.
• Do not infer CSM quality from the headline balance alone; product mix, new business profitability, assumptions, release pattern, and onerous contract movements matter.
• Separate policyholder / senior-creditor risk from subordinated noteholder recovery and loss-absorption risk.

Report Wording Cautions

• Use "expected support", "support expectations", or "strategic importance to Woori" rather than "guaranteed by Woori".
• Avoid describing the Tier II notes as ordinary senior debt or implying that the first reset date is a firm repayment date.
• When discussing K-ICS, identify whether the figure is preliminary, corrected, annual, or quarterly.
• Explain that FY2025 annual figures from mirrored extracts should be replaced with direct DART annual-report confirmation when available.

Follow-Up on Management Strategy, Investment Plans, and Financial Policy

• Woori's post-acquisition capital policy, dividend policy, integration with ABL Life, bancassurance strategy, and risk-management framework are the most important management follow-up items.
• Any capital injection, merger, portfolio transfer, reinsurance transaction, or significant restructuring after full ownership should be assessed for K-ICS, earnings, and policyholder / bondholder implications.

Items to Check for Ratings and Bond Investors

• Current international and domestic rating reports and sensitivities.
• The current rating and market treatment of the 2035 Tier II notes.
• Foreign-currency liquidity and hedging for the U.S. dollar subordinated notes.
• Any regulatory restrictions that could affect optional redemption, coupon payment, principal write-down, or capital recognition.